|
DRUG CLASS
|
CONCLUSION
(quotes from the NY State Dept of Health web site – see below)
|
AGENTS IN CLASS
|
|
ACE Inhibitors
|
“there is not adequate evidence of any drug with overall clinical superiority in this class.”
|
ACEI Class
Altace (ramipril), Mavik (trandolapril), benazepril (HCL), captopril, enalapril maleate, lisinopril and moexipril HCL. Accupril (quinapril HCL), Aceon (perindopril erbumine), Capoten (captopril), fosinopril sodium, Lotensin (benazepril HCL), Monopril (fosinopril sodium), Prinivil (lisinopril), quinapril HCL, Univasc (moexipril HCL), Vasotec (enalapril maleate), Zestril (lisinopril).
ACEI/Diuretic Combination Class
Uniretic (moexipril/hctz), benazepril HCL/hctz, captopril/hctz, enalapril maleate/hctz, and lisinopril/hctz. Accuretic (quinapril/hctz), Capozide (captopril/hctz), fosinopril/hctz, Lotensin HCT (benazepril HCL/hctz), Monopril HCT (fosinopril/hctz), Prinzide (lisinopril/hctz), Quinaretic (quinapril/hctz), Vaseretic (enalapril maleate/hctz), Zestoretic (lisinopril/hctz).
|
|
Angiotensin Receptor Blockers (ARB) / A2RAs
|
“there is not adequate evidence to demonstrate overall clinical superiority by any one agent in this class ”
|
ARB/AIIRA Class
Benicar (olmesartan medoxomil), Cozaar (losartan potassium), Diovan (valsartan), Micardis (telmisartan). Atacand (candesartan cilexetil), Avapro (irbesartan), Teveten (eprosartan mesylate).
ARB/AIIRA/Diuretic Combination Class
Benicar HCT (olmesartan medoxomil/hctz), Hyzaar (losartan/hctz), Diovan HCT (valsartan/hctz), Micardis HCT (telmisartan/hctz). Atacand HCT (candesartan cilexetil/hctz), Avalide (irbesartan/hctz), Teveten HCT (eprosartan/hctz).
|
|
Calcium Channel Blockers (Dihydropyridine class)
|
“there is not adequate evidence of overall clinical superiority to justify preferential availability of any specific DHP CCB ”
|
Afeditab CR, Dynacirc, Dynacirc CR, felodipine ER, isradipine, nicardipine HCl, Nifediac CC, Nifedical XL, nifedipine, nifedipine ER, nifedipine SA, Norvasc, Sular, Adalat, Adalat CC, Cardene, Cardene SR, Plendil, Procardia, Procardia XL
|
|
CCB / ACE Combinations
|
“there is not adequate evidence of clinical superiority to justify preferential availability of any CCB/ACEI combination product”
|
Lotrel, Tarka, Lexxel
|
|
Beta Blocker Combo Products
|
“no adequate evidence of overall clinical superiority to justify preferential availability of any one product ”
|
atenolol/chlorthalidone, bisoprolol fumarate/HCTZ, metoprolol tartrate/HCTZ, propranolol/HCTZ, Corzide, Inderide, Inderide LA, Lopressor HCT, Tenoretic, Timolide, Ziac
|
|
Beta Blockers:
|
“there is a lack of evidence to demonstrate overall comparative advantage for any one beta blocker ”
|
Acebutolol, atenolol, betaxolol, bisoprolol, labetalol HCl, metoprolol tartrate, nadolol, pindolol, propranolol HCl solution, propranolol HCl tablet, timolol maleate, Cartrol, Corgard, Inderal, Inderal LA, Innopran XL, Kerlone, Levatol, Lopressor, Sectral, Tenormin, Toprol XL, Trandate, Zebeta, Coreg
|
|
Statins
|
“there is not adequate evidence of overall clinical superiority to justify preferential availability of any one product”
|
Advicor, Altoprev, Crestor, Lescol, Lescol XL, Lipitor, Vytorin, Zocor, Caduet, lovastatin, Mevacor, Pravachol, Pravigard PAC
|
|
Triglyceride Lowering Agents
|
“there is not adequate evidence of overall clinical superiority to justify preferential availability of any one product ”
|
Gemfibrozil, Lofibra, Antara, fenofibrate, Lopid, Omacor, Tricor, Triglide
|
|
Topical Immunomodulators
|
“at this time there is no evidence to indicate that either product is more safe or effective overall. ”
|
Elidel, Protopic
|
|
Proton Pump Inhibitors
|
“Studies show that overall, each PPI works about as well as another for relieving symptoms ”
|
Nexium, Prevacid Capsule, Prilosec OTC, Aciphex, omeprazole, Prevacid Solutab, Prevacid Suspension, Prevacid NapraPAC, Prilosec, Protonix, Zegerid Packet, Zegerid Capsule
|
|
Anti-Emetics
|
“None was found consistently superior in efficacy or more tolerable than any other ”
|
Kytril tablet/solution, Zofran tablet/solution/ODT, Anzemet
|
|
Sedative Hypnotics
|
“there is no adequate evidence of overall clinical superiority to justify preferential availability of any one product ”
|
Ambien CR, chloral hydrate, estazolam, flurazepam, temazepam, triazolam, Ambien, Dalmane, Doral, Halcion, Lunesta, Prosom, Restoril, Rozerem, Somnote, Sonata
|
|
Triptans
|
“there is no adequate evidence of overall clinical superiority to justify preferential availability of any one product
|
Imitrex tablet/nasal/injection, Maxalt tablet/MLT, Amerge, Axert, Frova, Relpax, Zomig tablet/nasal/ZMT
|
|
Thiazolidinediones (TZDs)
|
“there does not appear to be conclusive evidence of difference in efficacy among the drugs ”
|
Actos, Actoplus met, Avandia, Avandamet, Avandaryl
|
|
Hepatitis C Agents
|
“no adequate evidence of overall clinical superiority to justify preferential availability of any one product”
|
PEG-Intron, PEG-Intron Redipen, Pegasys, Pegasys Convenience Pack
|
|
Bisphosphonates
|
“there is not adequate evidence of overall clinical superiority to justify preferential availability of any specific drug ”
|
Fosamax tablet, Fosamax solution, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva
|
|
Calcitonins
|
“there is not adequate evidence of overall clinical superiority to justify preferential availability of either product ”
|
Miacalcin, Fortical
|
|
Phosphate Binders and Regulators
|
“none of these drugs demonstrating overall advantages at all stages”
|
Fosrenol, Phoslo, Renagel
|
|
Long-Acting Narcotics
|
“there is no adequate evidence of overall clinical superiority to justify preferential availability of any one product ”
|
Duragesic, fentanyl patch, Kadian, morphine sulfate SR, Oramorph SR, Avinza, MS Contin, oxycodone HCl CR, Oxycontin
|
|
Intranasal Steroids
|
“there is currently no adequate evidence of overall clinical superiority to justify preferential availability of any one product ”
|
Nasacort AQ, Nasonex, Beconase AQ, Flonase, flunisolide, fluticasone, Nasarel, Rhinocort Aqua
|
|
Second Generation Anti-histamines
|
“no significant new evidence of clinical superiority to justify preferential availability of any one product”
|
OTC loratadine products (i.e. Claritin), OTC loratadine D products (i.e. Claritin D) Allegra, Allegra-D, Clarinex, Clarinex-D, fexofenadine, Semprex-D, Zyrtec, Zyrtec-D
|
|
Leukotriene Modifiers
|
“no conclusive evidence of difference in efficacy between the two drugs”
|
Accolate, Singulair
|
|
Short Acting Beta Agonists
|
“there is no conclusive evidence of difference in efficacy between the drugs in this category ”
|
albuterol, Maxair Autohaler, Proventil HFA, Ventolin HFA, Xopenex, Xopenex HFA, Accuneb, Alupent, metaproterenol, ProAir HFA, Proventil
|
|
Long Acting Beta Agonists
|
“no evidence of overall clinical superiority to justify preferential availability of either one of these products ”
|
Foradil, Serevent Diskus
|
|
Inhaled Corticosteroids
|
“there is not adequate evidence of overall clinical superiority of any one of these products to justify preferential availability … the medications in this category are equivalent ”
|
Advair Diskus, Advair HFA, Asmanex, Azmacort, Flovent HFA, Qvar, Aerobid, Aerobid-M, Pulmicort Turbuhaler
|
|
Inhaled Anticholinergics
|
“Based on a review of the available clinical information, it was recommended that these medications may be considered therapeutic alternatives ”
|
Atrovent, Atrovent HFA, Combivent, ipratropium, Spiriva, Duoneb
|